SuperworthSerina Therapeutics EPS SER
Diluted earnings per share by quarter and over the last twelve months, from 2018.
- Last 12 months, to Jun 30, 2026
- −$1.90
- Latest quarter, Q2 FY26
- −$0.55
- Fiscal year 2025
- −$1.92
Serina Therapeutics' earnings per share was −$1.90 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.55.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.92 | n/a |
| FY2024 | −$5.04 | n/a |
| FY2023 | −$2.66 | n/a |
| FY2022 | −$2.70 | −3100% |
| FY2021 | $0.09 | n/a |
| FY2020 | −$0.28 | n/a |
| FY2019 | −$0.33 | n/a |
| FY2018 | −$0.22 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.55 | n/a | −$1.90 | |
| Q1 FY26 | −$0.58 | n/a | −$2.01 | |
| Q4 FY25 | −$0.32 | n/a | −$1.92 | |
| Q3 FY25 | −$0.45 | −446% | −$1.90 | |
| Q2 FY25 | −$0.66 | −229% | −$1.32 | |
| Q1 FY25 | −$0.49 | n/a | −$0.15 | |
| Q4 FY24 | −$0.30 | n/a | −$5.04 | |
| Q3 FY24 | $0.13 | −43% | −$7.94 | |
| Q2 FY24 | $0.51 | +364% | −$7.84 | |
| Q1 FY24 | −$5.38 | −2790% | −$8.24 | |
| Q4 FY23 | −$3.20 | n/a | −$2.66 | |
| Q3 FY23 | $0.23 | n/a | −$1.96 |
Against its peers
Companies in Drug Manufacturers - General nearest Serina Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SERSerina Therapeutics | −$1.90 | |
| ATNMActinium Pharmaceuticals | $0.36 | |
| SPROSpero Therapeutics | $0.11 | |
| LFVNLifevantage | $0.40 | −46% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| Peer median | $0.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Serina Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.